Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Apolipoprotein D modulates F₂-isoprostane and 7-ketocholesterol formation and has a neuroprotective effect on organotypic hippocampal cultures after kainate-induced excitotoxic injury

Xin He, Jinatta Jittiwat, Ji-Hyun Kim, Andrew M. Jenner, Akhlaq A. Farooqui, Shutish C. Patel, Wei-Yi Ong

Apolipoprotein D (apoD), a member of the lipocalin family of transporter proteins binds a number of small lipophilic molecules including arachidonic acid and cholesterol. Recent studies showed a protective function of mammalian apoD as well as its insect and plant homologs against oxidative stress. In this study we investigated the effect of direct addition of exogenous human apoD protein purified from breast cystic fluid to rat hippocampal slice cultures after excitotoxic injury induced by the glutamate analog kainate. ApoD at a concentration of 10 μg/ml partially prevented loss of MAP2 immunostaining and LDH release from injured hippocampal neurons after kainate injury. ApoD also attenuated the increase in oxidative products of arachidonic acid and cholesterol, F₂-isoprostanes and 7-ketocholesterol, respectively, after kainate treatment. In view of the molecular structure of apoD which consists of an eight stranded β barrel that forms a binding pocket for a number of small hydrophobic molecules, we propose that apoD promotes its neuroprotective effects by binding to arachidonic acid and cholesterol thus preventing their oxidation to neurotoxic products such as 4-hydroxynonenal (4-HNE) and 7-ketocholesterol.

© 2009 Elsevier Ireland Ltd. All rights reserved.
Similar findings to those observed in Drosophila have been noted in vertebrates and even plants. Loss of mouse apoD function increases the sensitivity to oxidative stress and the levels of brain lipid peroxidation, and impairs locomotor and learning abilities [9]. In contrast, human apoD overexpression in the mouse brain produces opposite effects, increasing survival and preventing the rise of brain lipid peroxides after oxidant treatment [9]. ApoD has also been shown to provide resistance against coronavirus infections in mice [6]. Plants that overexpress apoD, likewise, show increased resistance to oxidative stress [4]. Cellular stresses that either cause extended growth arrest, such as hydrogen peroxide and UV light, or increase in proliferation, such as lipopolysaccharide treatment were found to increase apoD production in vitro. At the promoter level, NFκB, AP-1 and APRE-3 proved to be the elements implicated in the lipopolysaccharide response [7].

In this investigation, we studied the effect of direct addition of exogenous human apoD protein purified from human breast cystic fluid to rat hippocampal slice cultures after excitotoxic injury induced by the glutamate analog kainate (KA). Our results reveal a neuroprotective effect of apoD against kainate induced excitotoxicity, and suggest that this effect may be due to the ability of apoD to sequester and reduce the levels of arachidonic acid and cholesterol oxidation products, F2-isoprostanes and 7-ketocholesterol, respectively.

Organotypic hippocampal slice cultures were prepared as previously described [24], with minor modifications [13]. In brief, 10-day-old Wistar rat pups were anesthetized with intraperitoneal injections of 3.5% chloral hydrate, decapitated, and the brain removed. The hippocampi were dissected out, and sectioned transversely at 350 μM thickness using a tissue chopper. The slices were transferred to 30 mm Millicell CM culture plate inserts with 0.4 μM polytetrafluoroethylene membranes (Millipore, Bedford, MA, USA), and placed in 6-well culture plates containing culture medium (50% minimum essential medium, 25% horse serum, 25% Hanks balanced salt solution, supplemented with d-glucose [6.5 mg/ml], glutamine [2 mM] penicillin G [1 unit/ml] and streptomycin sulfate [1 μg/ml], pH 7.15). The slices were maintained at 37 °C, 100% humidity and 95% air and 5% CO2. The medium was changed to fresh medium every 3 days in culture. The effects of kainate and other agents were tested in hippocampal cultures after 14 days in vitro. The cultures were treated with KA (100 μM) for 3 h in serum free culture medium. The above dose and duration of kainate treatment has been shown to be toxic to neurons in hippocampal slices [13].

After kainate treatment, cultures were incubated with 1–10 μg/ml of apoD, diluted in fresh serum-free medium for 24 h. ApoD is present at 1–2 μg/ml concentration in the cerebrospinal fluid (CSF) of healthy humans, but levels in brain and CSF are several-fold increased in Alzheimer’s disease [26]. An 8–16 fold increase in apoD protein concentration is present in the hippocampus after entorhinal cortex lesions [27], and increased apoD immunoreactivity is found in hippocampal pyramidal neurons after kainate induced excitotoxicity in rats [18]. In view of the range of brain and CSF apoD concentrations in health and disease, we chose 1–10 μg/ml as the concentration to test in our experiments. Human apoD protein in these experiments was prepared as previously described [20]. Human breast cystic fluid was centrifuged at 35,000 × g for 2 h, followed by dialysis of the aqueous phase against K2HPO4 10 mM pH 7.4, and hydroxyapatite in same buffer. The protein elutes in the flow through and is concentrated on DEAE-agarose and eluted with 400 mM NaCl. Stock apoD was dissolved in serum-free medium and sterilized through a 0.22-μm filter. Controls consisted of untreated slices in serum free media, or slices incubated with 10 μg/ml of bovine serum albumin (BSA).

Assessment of neuronal damage was carried out by immunostaining and lactate dehydrogenase (LDH) assay. Immunostaining was carried out by fixing the slices in a fixative containing 4% paraformaldehyde in phosphate buffer (pH 7.4) for 30 min, followed by washing in phosphate buffered saline (PBS, pH 7.4) for 3 h to remove traces of fixative. The slices were then detached from the membranes and incubated with monoclonal antibody to microtubule-associated protein 2 (MAP2) (Sigma, 1:1000 dilution). The slices were washed in three changes of PBS and incubated for 1 h at room temperature in a 1:200 dilution of biotinylated horse anti-mouse IgG (Vector, Burlingame, USA). The slices were then reacted at room temperature for 1 h with an avidin-biotinylated horseradish peroxidase complex, and the reaction was visualized by treatment for 5 min in 0.05% 3,3-diaminobenzidine tetrahydrochloride (DAB) solution in Tris buffer containing 0.05% H2O2. The color reaction was stopped with several washes of Tris buffer, followed by PBS. The slices were mounted on gelatin-coated glass slides and counterstained with methyl green before coverslipping with Permount. The number of MAP2 positive neuronal cells in the CA fields of the hippocampal slices was counted in a “blind” manner on coded slides at 200× magnification with the help of a grid. At least six slices were quantified for each treatment. The mean number of stained cells/mm2 was then calculated for each treatment, and the results were subjected to statistical analyses, using one-way ANOVA with Bonferroni’s multiple comparison post-hoc test. P < 0.05 was considered significant.

LDH assay was carried out by collecting the culture media after various treatments and analysis using a LDH cytotoxicity detection kit (Roche, Basel, Switzerland) as follows: neuronal death = (A – Min/)(Max – Min)) × 100, in which A is LDH activity measured in media of test condition, Max is maximum LDH release after 3 h treatment with Triton X-100, defined as 100% of cell death, Min is the LDH activity in media of untreated slices. Media from three culture dishes in each treatment group was collected for a single experiment. The mean and standard deviation from three separate experiments were then calculated. The results were subjected to statistical analyses, using one-way ANOVA with Bonferroni’s multiple comparison post-hoc test. P < 0.05 was considered significant.

Other slices were pooled (12–16 slices as one sample) and analyzed by GC/MS for F2-isoprostanes and cholesterol oxidative products. Lipids were extracted, hydrolyzed and analyzed using GC/MS as described in detail previously [10,11,12]. Essentially lipids were extracted from homogenates using organic solvent (CHCl3/methanol 2:1, v/v, +0.005% butylated hydroxytoluene (BHT) and dried under a stream of N2. After addition of heavy isotopic standards of F2-isoprostanes, and the cholesterol oxidation products 7-ketocholesterol, samples were reconstituted in 1 ml PBS and 1 ml KOH (1 M in methanol) and hydrolyzed overnight at 23 °C in the dark under an argon atmosphere. Solid phase extraction was carried out using 60 mg MAX (mixed ion exchange, Waters, Milford, USA) columns. After elution of F2-isoprostanes and 7-ketocholesterol, extracts were dried under N2 gas, derivatized and analyzed by an Agilent 5975II gas chromatograph. Selected-ion monitoring was performed to monitor ions selected from each compound’s mass spectrum in order to optimize sensitivity and specificity. Quantification of F2-isoprostanes and 7-ketocholesterol was carried out by relating the total peak area of each analyte with their heavy isotopic internal standard. The results were subjected to statistical analyses, using one-way ANOVA with Bonferroni’s multiple comparison post-hoc test. P < 0.05 was considered significant.

Treatment of hippocampal slice cultures from rat brain with 100 μM kainate for 3 h caused neuronal injury in the hippocampal fields CA1 and CA3. This was shown by the light microscopic observation of decreased MAP2 immunostained pyramidal neurons in hippocampal CA fields. To investigate a possible neuroprotective effect of apoD, the kainate-injured hippocampal slices were treated with 1, 5, and 10 μg/ml of apoD. ApoD at a concentra-
Fig. 1. (A) Effect of apoD on neuronal survival after addition of kainate to hippocampal slices. CONT, KA and KA/ApoD indicate untreated, kainate, and kainate plus apoD-treated hippocampal slices as described in the methods. The cultures were fixed in 4% paraformaldehyde and then incubated overnight with monoclonal antibodies to MAP2. Arrows indicate MAP2 immunolabeled neurons. Scale = 300 μm. (B) Dose-dependent neuroprotective effect of apoD on cultured hippocampal slices. CONT, KA, KA/1, 5, 10 μg/ml apoD, and KA/10 μg/ml BSA indicate untreated, kainate treatment only, and kainate treatment followed by incubation for 24 h with 1, 5, 10 μg/ml of human apoD or 10 μg/ml BSA. (C) Effect of apoD on LDH release in hippocampal slice cultures. CONT, KA, KA/ApoD, and KA/BSA indicate untreated, kainate treatment only, and kainate treatment plus incubation for 24 h with 10 μg/ml of human apoD or 10 μg/ml BSA. KA-induced cell death quantified by measuring the percentage LDH leakage using a cytotoxicity detection kit (Roche). The values are mean ± standard deviation (n = 3). Results were analyzed by one-way ANOVA with Bonferroni’s multiple comparison post-hoc test. *P < 0.05 was considered significant. *Significant difference compared to CONT group; # significant difference compared to KA group.

Fig. 2. Effect of apoD on lipids and lipid peroxidation products in cultured hippocampal slices. F₂-isoprostanes (A) and 7-ketocholesterol (B) levels were measured by GC–MS in all the samples. CONT, KA, KA/ApoD, and KA/BSA indicate untreated, kainate treatment only, and kainate treatment plus incubation for 24 h with 10 μg/ml of human apoD or 10 μg/ml BSA. Data was normalized to the weight of the slices and expressed as mean ± standard deviation of three experiments. Results were analyzed by one-way ANOVA with Bonferroni’s multiple comparison post-hoc test. *P < 0.05 was considered significant. *Significant difference compared to CONT group; *significant difference compared to KA group.

The addition of 10 μg/ml partially prevented loss of MAP2 immunostaining from hippocampal neurons from kainate injury (Fig. 1A and B). Furthermore, assessment of LDH from kainate-treated tissues with and without addition of apoD showed significant decrease in LDH release from apoD-treated tissues (Fig. 1C). No protective effect was observed after addition of BSA (Fig. 1B and C). Together, these findings indicate a neuroprotective effect of apoD after kainate induced excitotoxicity that might be related to its ability to prevent the formation of lipid oxidation products. The above results are consistent with recent reports that showed that loss of mouse apoD function increases the sensitivity to oxidation stress and the levels of brain lipid peroxidation. In contrast, human apoD overexpression in the mouse brain produces opposite effects increasing survival and preventing the raise of brain lipid peroxides after oxidant treatment [9]. ApoD has also been shown to provide resistance against coronavirus infections in mice [6].

What may be basis for the neuroprotective effect of apoD? Kainate treatment caused a significant increase in levels of the breakdown product of arachidonic acid peroxidation, F₂-isoprostanes (Fig. 2A) and the cholesterol oxidation product, 7-ketocholesterol (Fig. 2B) indicating increased oxidative stress, but levels of these oxidation products were attenuated, in slices that were treated with 10 μg/ml apoD (Fig. 2A and B). No attenuation of increase in oxidation products after kainate treatment was observed in slices treated with 10 μg/ml BSA (Fig. 2A and B). These results extend previous findings which showed decreases in the
precursor to arachidonic acid, linoleic acid (18:2n6c), arachidonic acid itself (20:4n6) and the elongation product of arachidonic acid, adrenic acid (22:4n6), but increases in LA, eicosadienoic acid and docosahexaenoic acid in apoD knock-out compared to wild-type mice [29]. In view of the molecular structure of apoD which consists of an eight-stranded β barrel (β-clam) that forms a binding pocket form a number of small hydrophobic molecules, we propose that apoD is neuroprotective by binding to arachidonic acid and cholesterol thus preventing their oxidation to neurotoxic products such as 4-hydroxynonenal (4-HNE) [2] and 7-ketocholesterol [3,10,17]. The binding of apoD with arachidonic acid and cholesterol may also facilitate lipid transport mechanisms related to repair processes following KA-mediated toxicity. Further studies are necessary to elucidate factors that regulate the expression of apoD after neuronal injury.

Acknowledgement

This study was supported by a grant from the National Medical Research Council of Singapore (R-181-000-115-275).

References

[1] M. Balbin, J.M. Freije, A. Fuego, L.M. Sanchez, C. Lopez-Otín, Apolipoprotein D is the major protein component in cyst fluid from women with human breast gross cystic disease, Biochem. J. 271 (1990) 803–807.

[2] A.J. Bruce-Keller, Y.J. Li, M.A. Lovell, P.J. Kraemer, D.S. Gary, R.R. Brown, W.R. Marksbery, M.P. Mattson, 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurones and impairs visuospatial memory in rats, J. Neuropathol. Exp. Neurol. (1998) 257–267.

[3] J.T. Chang, L.Z. Liu, Neurotoxicity of cholesterol oxides on cultured cerebellar granule cells, Neurochem. Int. 32 (1998) 317–323.

[4] J.R. Charron, F. Oueller, M. Houde, F. Sarhan, The plant apolipoprotein D ortholog protects Arabidopsis against oxidative stress, BMC Plant Biol. 8 (2008) 86.

[5] F. Dandoy-Dron, F. Guillo, L. Benboudjema, J.M. Lora, S. Torres-Schumann, M. Voges, M. Allerhand, D.R. Flower, The lipocalin protein family: structure and function, Biochem. J. 15 (1996) 1–14.

[6] M.D. Ganfornina, S. Do Carmo, L.M. Sánchez, Y.S. López-Boado, C. López-Otín, Arachidonic acid binds to apolipoprotein D: implications for the protein’s function, FEBS Lett. 366 (1995) 53–56.

[7] J. Muffat, D.W. Walker, S. Benzer, Human ApoD, an apolipoprotein up-regulated in neurodegenerative diseases, extends lifespan and increases stress resistance in Drosophila, Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 7088–7093.

[8] W.Y. Ong, W.W. Goh, X.R. Lu, A.A. Farooqui, S.C. Patel, B. Halliwell, Increase in cholesterol and cholesterol oxidation products, and role of cholesterol oxidation products in kainic acid-induced neuronal injury, Brain Pathol. 13 (2003) 250–262.

[9] W.X. Ong, Y. He, S. Suresh, S.C. Patel, Differential expression of apolipoprotein D and apolipoprotein E in the kainate-lesioned rat hippocampus, Neuroscience 79 (1997) 359–367.

[10] C. Oordan, A. Navarro, C. Perez, A. Astudillo, E. Martinez, J. Tolivia, Apolipoprotein D expression in substantia nigra of Parkinson disease, Histochemistry 21 (2006) 361–366.

[11] R.C. Patel, D. Lange, W.J. McConathy, Y.C. Patel, S.C. Patel, Probing the structure of the ligand binding cavity of lipocalins by fluorescence spectroscopy, Protein Eng. 10 (1997) 621–625.

[12] E. Rassart, A. Bedirian, S. Do Carmo, O. Guinard, J. Sirois, L. Terrasse, R. Milne, Apolipoprotein D, Biochim. Biophys. Acta 1482 (2000) 185–198.

[13] M. Rickl, S. Wallrauch, R. Milne, E. Rassart, Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer’s patients, J. Neurochem. 71 (1998) 1643–1650.

[14] W.Y. Ong, E.W. Goh, X.R. Lu, A.A. Farooqui, S.C. Patel, B. Halliwell, Increase in cholesterol and cholesterol oxidation products, and role of cholesterol oxidation products in kainic acid-induced neuronal injury, Brain Pathol. 13 (2003) 250–262.

[15] E. Rassart, A. Bedirian, S. Do Carmo, O. Guinard, J. Sirois, L. Terrasse, R. Milne, Apolipoprotein D, Biochim. Biophys. Acta 1482 (2000) 185–198.

[16] M. Rickl, S. Wallrauch, R. Milne, E. Rassart, Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer’s patients, J. Neurochem. 71 (1998) 1643–1650.

[17] L. Terrisse, D. Séguin, P. Bertrand, J. Poirier, R. Milne, E. Rassart, Modulation of apolipoprotein D and apolipoprotein E expression in rat hippocampus after entorhinal cortex lesion, Brain Res. Mol. Brain Res. 70 (1999) 26–35.

[18] E.A. Thomas, J.K. Yao, Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D, Schizophr. Res. 89 (2007) 147–153.

[19] W.Y. Ong, E.W. Goh, X.R. Lu, A.A. Farooqui, S.C. Patel, B. Halliwell, Zinc supplementation inhibits lipid peroxidation and the development of atherosclerosis in rabbits fed a high cholesterol diet, Free Radic. Biol. Med. 42 (2007) 559–566.

[20] C.Y. Lee, A.M. Jenner, B. Halliwell, Rapid preparation of human urine and plasma samples for analysis of F2-isoprostanes by gas chromatography-mass spectrometry, Biochem. Biophys. Res. Commun. 320 (2004) 696–702.

[21] X.R. Lu, W.Y. Ong, B. Halliwell, L.A. Horrocks, A.A. Farooqui, Differential effects of calcium-dependent and calcium-independent phospholipase A2 inhibitors on kainate-induced neuronal injury in rat hippocampal slices, Free Radic. Biol. Med. 30 (2001) 1263–1273.

[22] W.J. McConathy, P. Alauzovic, Isolation and partial characterization of apolipoprotein D: a new protein moiety of the human plasma lipoprotein system, FERS Lett. 37 (1973) 178–182.

[23] J.H. Morais Cabral, G.L. Atkins, L.M. Sánchez, Y.S. López-Boado, C. López-Otín, Arachidonic acid binds to apolipoprotein D: implications for the protein’s function, FEBS Lett. 366 (1995) 53–56.

[24] J. Muffat, D.W. Walker, S. Benzer, Human ApoD, an apolipoprotein up-regulated in neurodegenerative diseases, extends lifespan and increases stress resistance in Drosophila, Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 7088–7093.

[25] W.Y. Ong, E.W. Goh, X.R. Lu, A.A. Farooqui, S.C. Patel, B. Halliwell, Increase in cholesterol and cholesterol oxidation products, and role of cholesterol oxidation products in kainic acid-induced neuronal injury, Brain Pathol. 13 (2003) 250–262.

[26] W.Y. Ong, Y. He, S. Suresh, S.C. Patel, Differential expression of apolipoprotein D and apolipoprotein E in the kainate-lesioned rat hippocampus, Neuroscience 79 (1997) 359–367.

[27] E. Rassart, A. Bedirian, S. Do Carmo, O. Guinard, J. Sirois, L. Terrasse, R. Milne, Apolipoprotein D, Biochim. Biophys. Acta 1482 (2000) 185–198.

[28] M. Rickl, S. Wallrauch, R. Milne, E. Rassart, Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer’s patients, J. Neurochem. 71 (1998) 1643–1650.

[29] L. Terrisse, D. Séguin, P. Bertrand, J. Poirier, R. Milne, E. Rassart, Modulation of apolipoprotein D and apolipoprotein E expression in rat hippocampus after entorhinal cortex lesion, Brain Res. Mol. Brain Res. 70 (1999) 26–35.

[30] E.A. Thomas, J.K. Yao, Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D, Schizophr. Res. 89 (2007) 147–153.

[31] D.W. Walker, J. Muffat, C. Rundel, S. Benzer, Overexpression of a Drosophila homolog of apolipoprotein D leads to increased stress resistance and extended lifespan, Curr. Biol. 16 (2006) 674–679.